Senseonics (NYSEAMERICAN:SENS) issued its earnings results on Tuesday. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.11, Morningstar.com reports. The company had revenue of $7.20 million during the quarter, compared to analyst estimates of $7.89 million. Senseonics updated its FY 2019 guidance to EPS.
SENS stock opened at $2.97 on Thursday. Senseonics has a 12-month low of $2.15 and a 12-month high of $5.29.
A number of hedge funds have recently added to or reduced their stakes in the stock. Amalgamated Bank acquired a new position in Senseonics in the fourth quarter valued at $28,000. First Allied Advisory Services Inc. acquired a new position in Senseonics in the fourth quarter valued at $35,000. Metropolitan Life Insurance Co. NY lifted its holdings in Senseonics by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 24,279 shares of the company’s stock valued at $63,000 after buying an additional 18,962 shares during the period. Bank of America Corp DE lifted its holdings in Senseonics by 620.3% in the fourth quarter. Bank of America Corp DE now owns 40,705 shares of the company’s stock valued at $106,000 after buying an additional 35,054 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in Senseonics by 78.0% in the fourth quarter. Principal Financial Group Inc. now owns 25,259 shares of the company’s stock valued at $65,000 after buying an additional 11,071 shares during the period. Institutional investors and hedge funds own 30.66% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/4220099/senseonics-sens-issues-earnings-results.html.
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Read More: How mutual funds make money
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.